The Comparative Effects of Pentoxifylline and Ursodeoxycholic Acid on IL-1β, IL-6, IL-8 AND TNF-α Levels in Nonalcoholic Fatty Liver

Eastern Journal of Medicine

Volumn 8, Issue 2, 2003, Pages 27-32

  Tuncer, Ilyas ^a   Uygan, Ismail ^a   Dülger, Haluk ^a   Türkdoǧan, Kürşat ^a   Şekeroǧlu, Ramazan ^a   Kösem, Mustafa ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Cytokines; Non alcoholic fatty liver; Pentoxifylline; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; NAUSEA; NONALCOHOLIC FATTY LIVER; PRURITUS;

EID: 0742318861     PISSN: 13010883     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Matteoni CA, Younossi ZM, Gramlich T, et al: Non-alcoholic fatty liver disease. Gastroenterology 116: 1413-1419, 1999.
2. Okolo P, Diehl AM: Non-alcoholic steatohepatitis and focal fatty liver. In: Feldman M, Sleisenger MH, Scharschmidt BF, (eds). Sleisenger&Fordtran's Gastrointestinal and Liver Disease. 6th edit. Philadelphia: WB Sunders, 1215-1220, 1998.
3. Oliver FWJ, Christopher PD: Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29: 495-501, 1998.
4. Tilg H, Diehl AM: Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 343: 1467-1476, 2000.
5. Diehl AM: Non-alcoholic steatohepatitis. Semin Liver Dis 19: 221-229, 1999.
6. Van-Furt AM, Seijmonsbergen EM, Langermans JA, et al: Effect of xanthine derivates and dexamethasone on Streptococcus pneumonia-stimulated production of tumor necrosis factor alpha, interleukin-1beta, and IL-10 by human leukocytes. Clin Diagn Lab Immunol 2: 689-692, 1995.
7. Shirin H, Rafael B, Aeed H, et al: Pentoxifylline prevents concanavalin A-induced hepatitis by reducing tumor necrosis factor a levels and inhibiting adhesion of T lymphocytes to extra cellular matrix. J Hepatol 29: 60-67, 1998.
8. Preaux AM, Mallat A, Rosenbaum J, et al: Pentoxifyllin inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 26: 315-322, 1997.
9. Sheth SG, Gordon FD, Chopra S: Non-alcoholic steatohepatitis. Ann Intern Med 126: 137-145, 1997.
10. Dixon JB, Bhathal PS, O'Brien PE: Non-alcoholic fatty liver disease: predictors of Non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91-100, 2001.
11. Neuschwander-Tetri BA: Fatty liver and non-alcoholic steatohepatitis. Clin Cornerstone 3: 47-57, 2001.
12. Laurin J, Lindor KD, Crippin JS, et al: Ursodexycholic acid or clofibrate in the treatment of non-alcoholic induced steatohepatitis. Hepatology 23: 1464-1467, 1996.
13. Kumar KS, Malet PF: Nonalcoholic steatohepatitis. Mayo Clin Proc 75: 733-739, 2000.
14. Angulo P, Lindor K: Treatment of nonalcoholic fatty liver: Present and emerging therapies. Semin Liver Dis 21: 81-88, 2001.
15. Fiatarone JR, Coverdale SA, Batey RG, Farrell GC: Non-alcoholic steaohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. J Gastroenterol Hepatol 6: 585-590, 1991.
16. West DA, James NH, Cosulich SC, et al: Role for tumor necrosis factor a receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferate nafenopin. Hepatology 30: 1417-1424, 1999.
17. Yin M, Wheeler MD, Kono H, et al: Essential role of tumor necrosis factor-a in alcohol-induced liver injury in mice. Gastroenterology 117: 942-952, 1999.
18. Yang SQ, Lin HZ, Lane MD, et al: Obesity increase sensitivity to endotoxin liver injury: implication for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94: 2557-2562, 1997.
19. Memon RA, Grunfeld C, Feingold KR: TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat Med 7: 2-3, 2001.
20. Huang YS, Wu JC, Chang FY, Lee SD: Interleukin-8 and alcoholic liver disease. Zhonghua Yi Xue Za Zhi 62: 395-401, 1999.
21. Funk JO, Ernst M, Schonharting MM, Zapel P: Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int J Immunopharmacol 17: 1007-1016, 1995.
22. Weinberg JB, Mason SN, Wortham TS: Inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1beta) messenger RNA (mRNA) expression in HL-60 leukaemia cells by pentoxifylline and dexamethasone: dissociation of acivicin-induced TNF-alpha and IL-1 beta mRNA expression from acivicin-induced monocytoid differentiation. Blood 79: 3337-3343, 1992.
23. Vromen A, Spira RM, Bercovier H, et al: Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. JPEN J Parenter Enteral Nutr 21: 233-234, 1997.
24. Rodrigues CM, Fan G, Ma X, et al: Anovel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101: 2790-2799, 1998.
25. Neuman MG, Shear NH, Bellentani S, Tiribelli C: Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology 115: 157-166, 1998.
26. Schwarzenberg SJ, Bundy M: Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats. Pediatr Res 35: 214-217, 1994.
27. Lin HZ, Yang SQ, Chuckaree C, et al: Metformin reverses fatty liver in obese, leptin-deficient mice. Nat Med 6: 998-1003, 2000.